These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22249976)

  • 1. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
    Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
    Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.
    Wei HB; Lu XS; Shang LH; Xu G; Hu J; Che DH; Liu F; Wu Y; Zhang GM; Yu Y
    Arch Med Res; 2011 Jul; 42(5):412-20. PubMed ID: 21827803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
    Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
    Yin M; Yan J; Voutsina A; Tibaldi C; Christiani DC; Heist RS; Rosell R; Booton R; Wei Q
    Lung Cancer; 2011 Jun; 72(3):370-7. PubMed ID: 21075476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer.
    KimCurran V; Zhou C; Schmid-Bindert G; Shengxiang R; Zhou S; Zhang L; Zhang J
    Adv Med Sci; 2011; 56(1):30-8. PubMed ID: 21536539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
    Hamilton G; Rath B
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].
    Wang J; Zhang Q; Zhang H; Wang Q; Yang X; Gu Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):337-41. PubMed ID: 20677561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
    Kalikaki A; Voutsina A; Koutsopoulos A; Papadaki C; Sfakianaki M; Yachnakis E; Xyrafas A; Kotsakis A; Agelaki S; Souglakos J; Mavroudis D; Georgoulias V
    Cancer Invest; 2015 Apr; 33(4):107-13. PubMed ID: 25647444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer.
    Mathiaux J; Le Morvan V; Pulido M; Jougon J; Bégueret H; Robert J
    Mol Diagn Ther; 2011 Jun; 15(3):159-66. PubMed ID: 21766907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
    Wei HB; Hu J; Shang LH; Zhang YY; Lu FF; Wei M; Yu Y
    Chin Med J (Engl); 2012 Aug; 125(16):2902-7. PubMed ID: 22932088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
    Suk R; Gurubhagavatula S; Park S; Zhou W; Su L; Lynch TJ; Wain JC; Neuberg D; Liu G; Christiani DC
    Clin Cancer Res; 2005 Feb; 11(4):1534-8. PubMed ID: 15746057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.